AOU Città della Salute e della Scienza di Torino – PO Molinette

Protocolli di Ricerca Clinica in ambito oncologico:

Disordini linfoproliferativi AOU CDSS

Divisione Universitaria di Ematologia (Prof. Benedetto Bruno)

Divisione Ospedaliera di Ematologia (Dott. Freilone Roberto)

Titolo:	OLYMPIA 5 "A Phase 3, Open Label, Randomized Study to Compare the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Combination with Lenalidomide Versus Rituximab in Combination with Lenalidomide in Relapsed/Refractory Participants with Follicular Lymphoma and Marginal Zone Lymphoma"
Patologia:	Marginal Zone Lymphoma RECIDIVA
Tipo di Studio:	INTERVENTISTICO, RANDOMIZZATO
Fase:	III
Principali criteri di inclusione:	• Have refractory disease or relapsed after at least one prior systemic chemo-immunotherapy or immunotherapy. Prior systemic therapy should have included at least one anti-CD20 antibody.
Principali criteri di esclusione:	• A malignancy other than NHL unless the participant is adequately and definitively treated and is cancer free for at least 3 years, with the exception of localized prostate cancer treated with hormone therapy or local radiotherapy (ie, pellets), cervical carcinoma in situ, breast cancer in situ, or nonmelanoma skin cancer that was definitively treated; • Known malabsorption syndrome or pre-existing gastrointestinal conditions that may impair absorption of lenalidomide (eg, gastric bypass, lap band, or other gastric procedures that would alter absorption); delivery of lenalidomide via nasogastric tube of gastrotomy is not allowed.
Sede e contatti	TORINO, MOLINETTE Divisione Universitaria di Ematologia PI: Prof.ssa Federica Cavallo (f.cavallo@unito.it) Study Coordinator: Irene Scavini (irene.scavini@unito.it)